Table 1.
Characteristics of the patients and the 3 groupsa
| Parameter | Patients, n (%) | Plasma VASH1 Level, fmol/mL | P Value | Low VASH1 | Medium VASH1 | High VASH1 | P Value |
|---|---|---|---|---|---|---|---|
| Age, y | .19b | ||||||
| Median | 67 | 69 | 68 | 64 | |||
| Range | 34‐83 | 52‐81 | 51‐77 | 34‐83 | |||
| Age ≧ 75 y | 15 (19.0%) | ||||||
| Gender | .34c | .92d | |||||
| Male | 51 (64.6%) | 274.7 ± 155.3 (74.2‐1190.4) | 17 | 18 | 16 | ||
| Female | 28 (35.4%) | 315.2 ± 213.4 (34.1‐1039.0) | 9 | 9 | 10 | ||
| Smoking history | .97e | ||||||
| Never smoker | 22 (27.8%) | 310.0 ± 217.2 (34.1‐1039.0) | .52c | 7 | 8 | 7 | |
| Ex‐smoker | 57 (72.2%) | 280.9 ± 161.5 (74.2‐1190.4) | 19 | 19 | 19 | ||
| Brinkman index range (median) | 0‐3120 (600) | 0‐1625 (600) | 0‐3120 (800) | 0‐2400 (500) | .73c | ||
| Performance status | |||||||
| 0 | 73 (92.4%) | 290.6 ± 183.7 (34.1‐1190.4) | .79c | 25 | 23 | 25 | |
| 1 | 6 (7.6%) | 270.6 ± 80.0 (180.3‐418.2) | 1 | 4 | 1 | ||
| Pathological stage | .99b | ||||||
| Stage IA | 31 (38.8%) | 294.6 ± 147.4 (118.7‐766.7) | 9 | 9 | 14 | .24f | |
| Stage IB | 20 (26.3%) | 297.7 ± 242.9 (34.1‐1190.4) | 9 | 3 | 8 | ||
| Stage IIA | 13 (16.3%) | 290.9 ± 230.2 (142.0‐1039.0) | 6 | 5 | 2 | ||
| Stage IIB | 6 (7.5%) | 271.3 ± 84.2 (155.2‐418.2) | 1 | 4 | 1 | ||
| Stage IIIA | 9 (11.3%) | 259.8 ± 31.8 (193.1‐301.3) | 1 | 6 | 2 | ||
| Pathology | .67d | .82e | |||||
| Adenocarcinoma | 45 (57.0) | 282.9 ± 180.2 (34.1‐1039.0) | 16 | 14 | 15 | ||
| Squamous cell carcinoma | 28 (35.4%) | 302.0 ± 190.7 (141.6‐1190.4) | 8 | 10 | 10 | ||
| Others | 6 (7.6%) |
Abbreviation: VASH1, vasohibin‐1.
a
Low VASH1, approximately 222; medium VASH1, 223‐281; and high VASH1, >282 fmol/mL.
b
One‐way analysis of variance.
c
t test.
d
t test for adenocarcinoma vs squamous carcinoma.
e
χ2 test.
f
χ2 test for IA vs non‐IA.